Abbas Lugemwa

Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa

James Hakim, Victor Musiime, Alex J. Szubert et al. · New England Journal of Medicine · 2017 · 224 citations · Full text

Public Health, Infectious Diseases, Pharmacotherapy +17

Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

Nicholas I. Paton, Cissy Kityo, Anne Hoppé et al. · New England Journal of Medicine · 2014 · 205 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Nicholas I. Paton, Joseph Musaazi, Cissy Kityo et al. · The Lancet HIV · 2022 · 137 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

Anna Turkova, Ellen White, Cissy Kityo et al. · UCL Discovery (University College London) · 2021 · 103 citations

Pharmacy, Pediatrics, Pharmacotherapy +16

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

Pauline Bollen, Cecilia L. Moore, Hilda Mujuru et al. · The Lancet HIV · 2020 · 49 citations · Full text

Pharmacy, Pediatrics, Pharmacology +17